Chapter 7 · Module 8

Hypertension in Diabetes Mellitus

Metabolic drug selection, cardiorenal integration, and the landmark trial evidence base

How Diabetes Drives Hypertension

Type 2 Diabetes — Insulin Resistance Pathways

Multiple Converging Mechanisms

Sympathetic activation: compensatory hyperinsulinemia stimulates the sympathetic nervous system → increased cardiac output + renal sodium retention
Renal sodium avidity: upregulated proximal tubular sodium-hydrogen exchanger → volume expansion → volume-dependent hypertension (this is why SGLT2 inhibitors are particularly effective)
RAAS activation: visceral adipose expresses all RAAS components; angiotensin II worsens insulin resistance → bidirectional feedback
Endothelial dysfunction: advanced glycation end products quench nitric oxide; hyperglycemia raises endothelin-1 and oxidative stress
Obstructive sleep apnea: highly prevalent in type 2 diabetes and obesity → sympathetic activation + aldosterone excess

Blood Pressure Targets — Key Trial Evidence

ACCORD BP & Guideline Targets

ACCORD BP (2010): intensive target below 120 vs standard below 140 mm Hg in type 2 diabetes → 41% relative risk reduction in stroke, but NO reduction in primary cardiovascular composite; more acute kidney injury, hypotension, hypokalemia
Practical target: below 130/80 mm Hg for most patients with diabetes — captures stroke benefit with manageable adverse events
Below 120 mm Hg systolic is NOT routinely recommended (ACCORD BP)
Below 140/90 mm Hg acceptable if lower target causes excessive medication burden
Avoid diastolic below 65–70 mm Hg in elderly patients or those with established coronary artery disease

Drug Class Selection in Diabetes — Metabolic Profile

Metabolic Consequences Determine Agent Preference in Diabetic Hypertension

Antihypertensive Classes: Glucose, Lipid, and Renal Effects

Drug Class	Glucose Effect	Lipid Effect	Key Notes for Diabetes
ACEi or ARB First-line	Favorable — reduces new-onset diabetes 20–25%	Neutral	Renoprotection independent of BP; ACEi for type 1 nephropathy (Lewis 1993); ARB for type 2 nephropathy (RENAAL, IDNT); no dual RAAS blockade
CCB (DHP) Preferred	Neutral	Neutral	ACCOMPLISH: superior to RAAS + HCTZ; less antiproteinuric than RAAS inhibitors — combine with, not substitute for, RAAS inhibitor in albuminuria
Thiazide (low dose) Caution	Adverse at high dose — hypokalemia impairs insulin secretion	Mildly adverse (high dose)	Indapamide most metabolically favorable; prefer low dose; combine with RAAS inhibitor to blunt hypokalemia; loop diuretic when eGFR below 30
Beta-blocker (non-selective) Avoid	Adverse — impairs insulin secretion, masks hypoglycemia (except diaphoresis)	Adverse — raises TG, lowers HDL	Atenolol: avoid (LIFE trial — inferior to losartan; metabolic burden; accumulates in CKD); propranolol: avoid without compelling indication
Carvedilol or Nebivolol Preferred beta-blocker	Neutral to favorable	Neutral to favorable	Carvedilol: combined alpha/beta — preferred beta-blocker in diabetes; Nebivolol: least metabolic impact of all beta-blockers; use when compelling indication requires beta-blocker
SGLT2 inhibitor Add-on	Highly favorable — lowers glucose + reduces visceral fat	Favorable	Systolic BP reduction 3–5 mm Hg; reduces intraglomerular pressure (tubuloglomerular feedback); EMPA-REG, CREDENCE, DAPA-CKD outcome benefit

SGLT2 Inhibitor Landmark Trials

Cardiovascular and Renal Outcome Evidence — Beyond Glucose Lowering

Key Trials Establishing the Cardiorenal Evidence Base

Trial (Year)	Agent / Population	Cardiovascular Outcome	Renal Outcome
EMPA-REG OUTCOME (2015)	Empagliflozin; type 2 diabetes with established cardiovascular disease	38% reduction in cardiovascular death; 35% reduction in heart failure hospitalization	39% reduction in renal composite endpoint
CANVAS (2017)	Canagliflozin; type 2 diabetes with cardiovascular risk	Significant reduction in cardiovascular events and heart failure hospitalization	Significant reduction in renal composite
DECLARE-TIMI 58 (2019)	Dapagliflozin; type 2 diabetes with cardiovascular risk or disease	Significant reduction in heart failure hospitalization	Significant reduction in renal composite
CREDENCE (2019)	Canagliflozin; type 2 diabetes with CKD (eGFR 30–90) on RAAS inhibitor	Significant reduction in cardiovascular events	40% reduction in primary renal composite; 30% reduction in ESRD
DAPA-CKD (2020)	Dapagliflozin; CKD with or without diabetes (eGFR 25–75)	Significant cardiovascular death reduction	39% reduction in primary composite — first trial showing renal benefit independent of diabetes status

Integrated Cardiorenal Management in Type 2 Diabetic Hypertension

Foundation Regimen

Building the Antihypertensive Regimen

Step 1: ACEi or ARB — anchor drug for renoprotection (mandatory with albuminuria above 30 mg/g)
Step 2: Add SGLT2 inhibitor — cardiorenal outcome benefit plus modest BP lowering; reduces intraglomerular pressure complementary to RAAS inhibitor
Step 3: Add CCB (amlodipine) — metabolically neutral, ACCOMPLISH-preferred combination partner
Step 4 (resistant): Spironolactone 25–50 mg (PATHWAY-2); finerenone preferred in diabetic CKD with albuminuria on RAAS + SGLT2 inhibitor
GLP-1 receptor agonist: add for established cardiovascular disease — modest BP reduction plus LEADER/SUSTAIN-6 cardiovascular outcome benefit

Resistant Hypertension & Drug Interactions

Diabetes-Specific Pitfalls

NSAIDs: frequently used for neuropathic pain; raise BP 3–5 mm Hg; blunt RAAS inhibitors and diuretics; increase acute kidney injury risk — substitute acetaminophen, duloxetine, or pregabalin
SGLT2 inhibitor + diuretic: additive natriuresis may cause volume depletion and hypotension — consider reducing diuretic dose; monitor BP and eGFR at 4 weeks
Obstructive sleep apnea: present in ~80% of resistant hypertension cases; screen all obese type 2 diabetic patients with resistant hypertension
Atenolol: avoid in diabetes — inferior cardiovascular outcomes (LIFE trial), masks hypoglycemia, accumulates in CKD
High-dose thiazides: avoid — hypokalemia impairs insulin secretion and worsens glycemic control

The Three-Drug Cardiorenal Package for Type 2 Diabetic CKD with Albuminuria

RAAS inhibitor (efferent arteriole dilation, angiotensin II fibrosis blockade) + SGLT2 inhibitor (tubuloglomerular feedback restoration, afferent constriction) + Finerenone (aldosterone-mediated inflammation and fibrosis blockade) = triple renoprotective strategy. Each targets a distinct pathway; combination is supported by KDIGO and ADA 2024 guidelines. Monitor potassium closely with all three — each can raise potassium, though SGLT2 inhibitors partially offset this through natriuresis.